Hans van Houte sold $28k of NRIX
Chief Financial Officer at Nurix Therapeutics, Inc.. 2,438 shares at an average of $11.50, traded Apr 30, 2025, filed Apr 30, 2025.
Score components
- +22RoleCFO
- +5Trade size$28k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.8%, 3m +3.0%, 6m +1.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001549595-25-000059, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 30, 2025 | MOption exercise Common Stock | +2,886 | $0.00 | $0 | 36,610 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 38,610 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 42,360 | Apr 30, 2025 |
| Apr 30, 2025 | SOpen-market sale Common Stock | -2,438 | $11.50 | $28k | 39,922 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,886 | $0.00 | $0 | 8,659 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 8,000 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 30,000 | Apr 30, 2025 |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 20Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $100k 4,111 shares | -3% | |
| 5Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $109k 4,356 shares | -4% | |
| 32Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $116k 4,761 shares | -11% | |
| 31Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $382k 16,589 shares | -65% | |
| 24Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $90k 3,847 shares | -3% | |
| 29Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $90k 3,847 shares | -16% | |
| 30Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $67k 2,845 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.